Noninterventional Open-Label Trial Investigating the Efficacy and Safety of Ectoine Containing Nasal Spray in Comparison with Beclomethasone Nasal Spray in Patients with Allergic Rhinitis

Table 2

Development of single nasal symptoms during the study. Improvement, deterioration, or unchanged status of single symptoms was assessed by patients and investigators.

	Patients’ assessment		Total	Physicians’ assessment		Total
	Group 1	Group 2		Group 1	Group 2
Rhinorrhoea
Reduced	11 (47.8%)	12 (48.0%)	23 (47.9%)	17 (68.0%)	22 (88.0%)	39 (78.0%)
Unchanged	9 (39.1%)	11 (44.0%)	20 (41.7%)	6 (24.0%)	3 (12.0%)	9 (18.0%)
Deteriorated	3 (13.0%)	2 (8.0%)	5 (10.4%)	2 (8.0%)	0 (0.0%)	2 (4.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher’s exact test	𝑃=𝟎.𝟗𝟏𝟗			𝑃=𝟎.𝟐𝟐𝟏
Nasal itching
Reduced	7 (30.4%)	12 (48.0%)	19 (39.6%)	20 (80.0%)	22 (88.0%)	42 (84.0%)
Unchanged	13 (56.5%)	10 (40.0%)	23 (47.9%)	4 (16.0%)	2 (8.0%)	6 (12.0%)
Deteriorated	3 (13.0%)	3 (13.0%)	6 (12.5%)	1 (4.0%)	1 (4.0%)	2 (4.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher’s exact test	𝑃=𝟎.𝟒𝟒𝟎			𝑃=𝟎.𝟖𝟑𝟎
Nasal obstruction
Reduced	11 (47.8%)	10 (40.0%)	21 (43.8%)	18 (72.0%)	22 (88.0%)	40 (80.0%)
Unchanged	7 (30.4%)	13 (52.0%)	23 (41.7%)	6 (24.0%)	2 (8.0%)	8 (16.0%)
Deteriorated	5 (21.7%)	2 (8.0%)	7 (14.6%)	1 (4.0%)	1 (4.0%)	2 (4.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher’s exact test	𝑃=𝟎.𝟐𝟓𝟖			𝑃=𝟎.𝟑𝟒𝟕
Sneezing
Reduced	5 (21.7%)	12 (48.0%)	17 (35.4%)	18 (72.0%)	23 (92.0%)	41 (82.0%)
Unchanged	10 (43.5%)	11 (44.0%)	21 (43.8%)	3 (12.0%)	2 (8.0%)	5 (10.0%)
Deteriorated	8 (34.8%)	2 (8.0%)	10 (20.8%)	4 (16.0%)	0 (0.0%)	4 (8.0%)
Total	23 (100.0%)	25 (100.0%)	48 (100.0%)	25 (100.0%)	25 (100.0%)	50 (100.0%)
Fisher’s exact test	𝑃=𝟎.𝟎𝟑𝟗			𝑃=𝟎.𝟏𝟏𝟓